Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma

Zhiying Shao, Andrew Z. Wang, Daniel J. George, Tian Zhang

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

The treatment of metastatic renal cell carcinoma (RCC) and urothelial carcinoma (UC) remains a major challenge. Past research has implicated the immune system in tumor surveillance of both malignancies, leading to the application of immunotherapy agents for both cancers. Among them, the most promising agents are the checkpoint blockade drugs, such as antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death receptor 1 (PD-1), and PD-1 ligand (PD-L1). In normal physiology, these immune checkpoints act as inhibitory signals to fine-tune the duration and strength of immune reactions, which is pivotal for maintaining self-tolerance. However, tumor cells also utilize immune checkpoint pathways to evade anti-tumor immune response, leading to disease progression and metastasis. Thus, there has been intense preclinical and clinical effort focused on the application of checkpoint inhibitors in metastatic RCC and UC. To date, nivolumab (anti-PD-1) and atezolizumab (anti-PD-L1) have been approved for the treatment of metastatic RCC and UC, respectively. Despite these successes, challenges remain in how to further improve response rates to immunotherapy and how to select patients that will benefit from this approach. In this report, we review existing data and research on immunotherapy in metastatic RCC and UC.

Original languageEnglish (US)
Pages (from-to)268-277
Number of pages10
JournalAsian Journal of Urology
Volume3
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Keywords

  • Atezolizumab
  • Immune checkpoint inhibitors
  • Nivolumab
  • Pembrolizumab
  • Renal cell carcinoma
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma'. Together they form a unique fingerprint.

Cite this